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host origin, and the antigen-presenting cells (APC) in
the periphery, which are entirely of donor origin in full
chimeras. These T cells are ineffective at mounting rele-
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Bone Marrow Transplantation Section
Transplantation Biology Research Center
Massachusetts General Hospital/Harvard vant donor-restricted immune responses and lack host
APC that could induce generation of host-restricted re-Medical School
Boston, Massachusetts 02129 sponses. In contrast, mixed chimeras have a lifelong
source of host APC to allow effective generation of host-
restricted immune responses (reviewed in Wekerle and
Sykes, 1999). Although the premise that hematopoietic
Background: Mixed Chimerism as an Approach cells do not participate in positive selection is controver-
to Tolerance Induction sial and has recently been challenged (Zinkernagel and
Induction of specific immunologic tolerance to donor Althage, 1999), studies of anti-viral CTL responses in
antigens would avoid both chronic graft rejection and mixed chimeras showed exquisite specificity for recipi-
the side effects associated with chronic, nonspecific ent-derived MHC restricting elements (Ruedi et al.,
immunosuppressive therapy. It has been known for 1989).
many years that hematopoietic chimerism, when estab- In mixed chimeras, hematopoietic cells from both the
lished in preimmune animals, leads to transplantation recipient and the donor locate to the thymus and hence
tolerance. Exposure of the developing immune system delete both host-reactive and donor-reactive T cells,
to donor antigen results in education of the immune resulting in a peripheral T cell repertoire that is tolerant
system to regard the donor as “self.” Achieving a similar toward the donor and the host (Tomita et al., 1994a;
outcome in recipients with an established immune sys- Manilay et al., 1998a). This results in a third advantage of
tem presents additional challenges, as it requires abla- mixed over full chimerism. Although nonhematopoietic
tion or tolerization of the preexisting immune system. thymic stromal cells have some capacity to induce dele-
Immunoablation and myeloablation with lethal total tional tolerance, the capacity of hematopoietic cells,
body irradiation (TBI) allows reconstitution with alloge- especially dendritic cells, to do so is particularly power-
neic hematopoietic cells and induction of transplanta- ful. Thus, because there are host- as well as donor-
tion tolerance in adult rodents (reviewed in Wekerle and derived hematopoietic APC in the thymi of mixed (but
Sykes, 1999). Such animals are referred to as “full” he- not full) chimeras, intrathymic deletion of host-reactive
matopoietic chimeras. In contrast, “mixed” chimerism cells in addition to donor-reactive cells occurs in mixed
refers to a state in which allogeneic hematopoietic cells chimeras to a greater extent than in full chimeras (Yoshi-
coexist with recipient cells. Mixed chimerism can be kai et al., 1990; Tomita et al., 1994a). While there are
induced in adult mice by reconstituting lethally irradiated clearly other mechanisms by which host-reactive T cells
animals with a mixture of T cell–depleted allogeneic and can be tolerized in this setting, tolerance due to T cell
host-type marrow, by administering allogeneic marrow “anergy” can be broken under certain conditions (Rams-
following treatment with high doses of total lymphoid dell and Fowlkes, 1992), whereas T cells deleted in the
irradiation, or with non-myeloablative regimens (see be- thymus stand no chance of causing pathology under
low). In such animals, specific tolerance to donor tissue any circumstance.
grafts and host antigens is produced (reviewed in Wek-
erle and Sykes, 1999).
Mixed Chimerism versus Other Methods of Tolerance
Induction: the Importance of Central Deletion
Advantages of Mixed Chimerism over Full Chimerism Since deletional tolerance is particularly robust, host-
There are several advantages of mixed chimerism over versus-graft tolerance induced in this way allows accep-
full chimerism as an approach to the induction of trans- tance of highly immunogenic primary skin or small bowel
plantation tolerance. One is that mixed chimerism can grafts across the most extensive histocompatibility bar-
be achieved with non-myeloablative regimens, which riers (reviewed in Wekerle and Sykes, 1999). Other types
are generally less toxic than myeloablative conditioning, of grafts, such as primarily vascularized hearts and kid-
as is discussed further below. A second advantage is neys, are tolerogenic in rodents but unfortunately may
the superior immunocompetence of mixed compared to be less so in large animals. Indeed, there are many
full chimeras produced across complete MHC barriers. successful protocols for inducing tolerance to heart,
If a tolerance-inducing protocol is to be practicable for kidney, and liver allografts in rodents. It appears that
cadaveric organ transplantation, then it must be suc- giving sufficient immunosuppression to inhibit the initial
cessful across complete histocompatibility barriers, rejection of the graft allows the inherently tolerogenic
since HLA matching is highly impractical in this situation. properties of these allografts to ultimately prevail. The
However, induction of full chimerism across complete tolerance is often erroneously attributed to the initial
MHC barriers may be associated with immunoincompe- treatment that was given to the recipient, rather than to
tence resulting from the full MHC disparity between the the primarily vascularized allograft. Unfortunately, ef-
positive selecting elements in the thymus, which are of forts to translate such protocols into large animals have
usually failed. Information on the molecular mechanisms
of tolerance induced by nondeletional mechanisms is* E-mail: megan.sykes@tbrc.mgh.harvard.edu.
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just beginning to emerge, making it far more difficult to chimerism have moved the mixed chimerism approach
to tolerance induction toward clinical application. Thesetranslate these complex phenomena into the clinic. In
requirements are summarized in Figure 1, and their de-view of differences between species in the actions, tox-
lineation began with the demonstration that fully MHC-icities, and dose responses of various drugs and biologi-
mismatched marrow engraftment and specific tolerancecal agents, without a clear understanding of exactly
could be achieved by pretreating recipients with deplet-what pathways are relevant and without clear markers
ing doses of anti-CD4 and anti-CD8 mAbs along withof the tolerant state it is very difficult to translate such
a sublethal dose (6 Gy) of total body irradiation (TBI)approaches to human recipients. In contrast, successful
(Cobbold et al., 1986) or even with a minimally myelosup-engraftment of donor marrow has been associated with
pressive (Tomita et al., 1994b) dose of TBI (3 Gy), iftransplantation tolerance in large animals (Kawai et al.,
additional selective irradiation was given to the thymic1995; Fuchimoto et al., 2000; Huang et al., 2000) and
area (referred to as thymic irradiation [TI]) (Sharabi andhumans (reviewed in Dey et al., 1998).
Sachs, 1989). TI is needed to overcome residual allore-As might be expected, tolerance induced by intra-
activity that persists in the thymus (Nikolic et al., 2001b),thymic deletional mechanisms is systemic, as shown by
since mAb doses that effectively deplete peripheral Tboth in vivo and in vitro studies (reviewed in Wekerle
cells are insufficient to deplete alloreactive thymocytesand Sykes, 1999). While anergy may play a role in toleriz-
(Nikolic et al., 2001a) (Figure 1). TI also creates someing the few peripheral T cells that escape depletion with
hematopoietic “space,” leading to increased donor plur-mAbs in some protocols (Tomita et al., 1994a), long-
ipotent stem cell engraftment, and additionally in-term tolerance appears to be maintained purely by a
creases the intrathymic engraftment of thymocyte pro-deletional mechanism. Using donor MHC-specific anti-
genitors, which appears to be under separate regulationbody to eliminate donor chimerism from established
from engraftment in the marrow compartment (Sykes etmixed chimeras leads to a loss of tolerance and to the
al., 1998). Because the conditioning regimen does notde novo appearance in the periphery of T cells with Vb
ablate the recipient’s hematopoietic system (Sharabithat recognize superantigens presented by the donor.
and Sachs, 1989; Tomita et al., 1994b) and hence isHowever, if the recipient thymus is removed prior to
referred to as “non-myeloablative,” a state of mixedelimination of chimerism with antibody, specific toler-
hematopoietic chimerism is achieved when allogeneicance to the donor is preserved, and donor-reactive TCR
marrow engrafts. Recently, a number of modificationsdo not appear in the periphery (Khan et al., 1996). Thus,
have made these conditioning regimens even less toxic.chimerism is needed only in the thymus and not in the
These include the replacement of TI with a second injec-periphery in order to ensure persistent tolerance. This
tion of depleting anti-T cell mAbs (reviewed in Wekerleis consistent with a purely deletional mechanism, since
and Sykes, 1999), with pretransplant CYA treatment (Ni-anergy and suppression generally require the relevant
kolic et al., 2000), or with a costimulatory blocker (Wek-antigen to maintain the tolerance. The result also dem-
erle et al., 1999b). Both TI and host T cell depletingonstrates that the thymus is sufficiently functional in
mAbs can be omitted by using costimulatory blockadesenescent mice to generate donor-reactive T cells if
(Wekerle et al., 1998). TBI can be omitted by administer-donor antigen is not continuously present in the thymus.
ing very high marrow doses (reviewed in Wekerle andSince thymic APC are continually turning over, this em-
Sykes, 1999), and all preconditioning can be eliminatedphasizes the need for true hematopoietic stem cell en-
by giving a high dose of fully MHC-mismatched donorgraftment at sufficient levels in order to ensure an unin-
marrow followed by a single injection of each of twoterrupted supply of donor APC in the recipient thymus
costimulatory blockers (Wekerle et al., 2000) or repeatedfor the life of the mixed chimera. The absence of sup-
injections of anti-CD40 ligand (Durham et al., 2000). Ap-pressive tolerance mechanisms makes them particularly
parently, the administration of very large hematopoieticvulnerable to breaking of tolerance when nontolerant T
cell doses can overcome the requirement to create
cells emerge from the thymus after intentional depletion
space with myelosuppressive treatment in order to
of donor antigen or after exogenous administration of
achieve marrow engraftment (Stewart et al., 1993; Sykes
nontolerant host-type T cells (Khan et al., 1996). et al., 1998) (Figure 1).
The ability to replace recipient T cell depletion with
Development of Nontoxic Approaches to Mixed costimulatory blockade is encouraging for several rea-
Chimerism Induction sons. First, it has been difficult to achieve T cell depletion
Despite the advantages described above, induction of with antibodies in large animals and humans that is as
mixed chimerism has not yet been routinely applied in exhaustive as that achieved in the above rodent models,
human recipients of organ grafts. Application of hemato- perhaps due to the use of inadequate doses or subopti-
poietic cell transplantation (HCT) for tolerance induction mal reagents. A second concern is that, if sufficiently
in humans has been largely prohibited by the toxicity of exhaustive T cell depletion could be achieved in hu-
the host conditioning traditionally used to allow alloge- mans, T cell recovery from the thymus might be danger-
neic marrow engraftment and by the formidable problem ously slow, especially in older individuals. With increas-
of GVHD encountered when even partial HLA barriers ing age, the adult human thymus becomes progressively
were transgressed. While GVHD can be ameliorated by more sluggish in achieving immune reconstitution after
donor marrow T cell depletion, this approach increases ablative treatments or with antiretroviral therapy in pa-
the incidence of failure of marrow engraftment, which tients with HIV infection (reviewed in Haynes et al., 2000).
can cause fatal aplasia in myeloablated recipients. However, it is also clear that normal adults do have
In recent years, however, an evolving understanding thymic function, even in old age (Haynes et al., 2000),
and the capacity for regeneration and “rebound” thymo-of the minimal requirements for achievement of lasting
Review
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Figure 1. Schematic Representation of the
Requirements for Achieving Durable Mixed
Chimerism and Transplantation Tolerance
Donor and host hematopoietic cell-derived
elements are distinguished by the different
fills, as indicated in the figure. (A) Recipient
anti-donor T cell reactivity in the peripheral
immune system must be overcome in order
to allow donor hematopoietic stem cells to
engraft. (B) When “standard” stem cell doses
are administered, a manipulation of the recip-
ient (e.g., low-dose TBI, myelosuppressive
drug, etc.) is required to make space for en-
graftment of donor hematopoietic cells in the
recipient’s marrow microenvironment. If very
large doses of donor stem cells are given,
some of these may engraft in the recipient
marrow without a manipulation to create
space. (C) Specific manipulations (e.g., thy-
mic irradiation, costimulatory blockade, pre-
transplant cyclosporine) are needed to over-
come intrathymic alloreactivity, which can
otherwise cause intrathymic rejection of do-
nor cells, even when good peripheral en-
graftment is initially achieved. If intrathymic
alloreactivity is adequately blocked, the prog-
eny of donor stem cells (e.g., donor dendritic
cells) will survive and, along with host marrow-derived cells, contribute to negative selection of all newly developing thymocytes. Thus, the
thymus exports new T cells that are specifically deleted of donor- and host-reactive cells. Since donor and host hematopoietic stem cells
both contribute to hematopoiesis on an ongoing basis, a life-long supply of donor and host APC in the thymus assures life-long deletional
tolerance.
poiesis in an individual whose thymus has not been graft acceptance (Wekerle et al., 1998, 2000). Either
CTLA4Ig or anti-CD154 mAb overcame the requirementsubjected to injury by the above agents is largely un-
known. Nevertheless, it would clearly be desirable to for thymic irradiation or repeated injection of T cell–
depleting antibodies in mice receiving a T cell depletionminimize the degree and duration of T cell depletion
used in protocols for the induction of mixed chimerism. regimen that was in itself insufficient to permit induction
of lasting chimerism (Wekerle et al., 1999b). In fact, aThe ability to do this by replacing some (Ito et al., 2001)
or all (Wekerle et al., 1998, 2000; Durham et al., 2000) single injection of anti-CD40L mAb is sufficient to allow
BMT to induce tolerance of CD4 cells in mice receivingof the T cell depleting antibodies with a single injection
of costimulatory blockers is therefore of considerable an injection of depleting anti-CD8 mAb (Ito et al., 2001).
The anti-CD40L mAb is required only to block the inter-interest.
While long-term tolerance is maintained by intrathymic action between CD40L and CD40 and not to target acti-
vated T cells for depletion or to signal to the CD4 celldeletion in mixed chimeras prepared with costimula-
tory blockade (Wekerle et al., 1998, 2000; Ito et al., 2001), (J. Kurtz et al., submitted). These results indicate that
CD4 cell-mediated alloresistance to bone marrow graftsthe mechanisms of initial tolerance in animals receiving
BMT under cover of costimulatory blockade instead of is exquisitely dependent on CD40–CD40L interactions.
This is somewhat surprising, since CD40-independentT cell depletion are not fully understood. Large numbers
of alloreactive T cells present in the peripheral lymphoid pathways can activate APC to induce antiviral CD4 cell
responses. Much remains to be learned about the mech-tissues of these animals must be tolerized. Peripheral
deletion of donor-reactive cells through a combination anisms by which CD4 T cells are tolerized to alloantigens
when APC activation via CD40 is blocked.of activation-induced cell death and “passive cell death”
appears to play a role (Wekerle et al., 1998, 2000, 2001). GVHD does not occur in the rodent models discussed
above, despite the use of unseparated donor bone mar-However, donor-specific tolerance is complete in mixed
lymphocyte reactions by 1 week posttransplant, when row cells (BMC). This is most readily explained by the
continued presence of the T cell–depleting or costimula-deletion of donor-reactive CD4 cells is only partial (J.
Kurtz et al., submitted), suggesting that mechanisms in tory blocking antibodies in the serum of the hosts at
the time of BMT (Tomita et al., 1996). These levels areaddition to deletion are involved in the early tolerization
of peripheral CD4 cells by donor bone marrow in the sufficient to prevent alloreactivity by the relatively small
number of mature T cells in the donor marrow.presence of costimulatory blockade.
Although attractive because they do not require host T
cell depletion, one limitation to the use of costimulatory Comparison of Costimulatory Blockade
with and without HCTblockade in place of peripheral T cell depletion to
achieve allogeneic bone marrow engraftment is that it A donor-specific transfusion (DST) model is of particular
interest for comparison to the mixed chimerism model,is not 100% successful, i.e., a fraction of animals fails
to achieve permanent chimerism or donor-specific skin since both models involve the use of hematopoietic cells
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in the presence of costimulatory blockade, but only the tolerance and chimerism are obliterated by the infusion
mixed chimerism model allows engraftment of hemato- of relatively small numbers of nontolerant recipient-type
poietic stem cells and intrathymic deletion as a mecha- spleen cells in this model (J. Kurtz et al., unpublished
nism maintaining tolerance in the long term (Wekerle et data). Since hematopoietic stem cell engraftment en-
al., 1999b, 2000). Indeed, DST and anti-CD40L allows sures complete central deletional tolerance in these
long-term skin graft survival in the majority of animals long-term chimeras and peripheral deletion is also com-
only if they are thymectomized prior to transplant (Mar- plete over time (Wekerle et al., 1998, 1999a, 2000; Ito et
kees et al., 1998). The inability to maintain tolerance in al., 2001), there may be insufficient donor-reactive T
the presence of a thymus indicates the failure to estab- cells present to maintain suppressive mechanisms if
lish central tolerance in the absence of substantial chi- they were present in the initial peripheral tolerance in-
merism. In addition, the inability to resist breaking of duction phase.
tolerance by new thymic emigrants in this model argues
that powerful peripheral regulatory mechanisms (sup- Is NK Cell Tolerance Induced by Mixed Chimerism?
pression) are not operative in these animals. However, While NK cells resist short-term myeloid progenitor en-
regulatory mechanisms may play a role in the initial graftment, they actually present a relatively weak barrier
suppression of alloresponses, since depletion of CD4 to the engraftment of allogeneic pluripotent hematopoi-
cells abrogated skin graft acceptance (Markees et al., etic stem cells (Lee et al., 1996; Aguila and Weissman,
1998). 1996). Nevertheless, NK cells might pose a more signifi-
A number of other models have utilized costimulatory cant barrier to HLA-mismatched human marrow en-
blockade without hematopoietic cells to induce toler- graftment, in which stem cell and progenitor cell num-
ance. When performed in extensively MHC-mismatched bers in the donor inoculum may be more limited. The
combinations, these studies have achieved functional question of whether or not NK cells are tolerized by
“tolerance” only in rodent models of cardiac or islet induction of mixed chimerism is relevant to the long-
allografts (Li et al., 1998) or islet xenografts (Lehnert et term stability of the chimerism. Such tolerance might
al., 2000) and not in the more stringent models of primary require that each individual NK cell express inhibitory
skin grafting or large animal vascularized organ or islet receptors for two completely disparate sets of MHC
allografts, in which prolongation has been seen without molecules on donor and host cells. However, the ob-
long-term tolerance (Kenyon et al., 1999; Kirk et al., served changes in the expression of Ly-49 receptors
1999; Tramblay et al., 1999). One exception is the use among donor and host NK cells of mixed chimeras are
of a short course of rapamycin with anti-CD40L and not consistent with such a mechanism. The presence of
CTLA4Ig, which allows long-term acceptance of primary the MHC ligand (on hematopoietic or nonhematopoietic
skin allografts across full MHC barriers in mice (Li et al., cells) for a given Ly-49 receptor leads to an antigen
1999). Unlike mixed chimeras induced with costimula- dose-related reduction in the level of that receptor on
tory blockade or T cell depletion, in which the systemic donor and host NK cells (Sykes et al., 1993; Manilay et
nature of tolerance can be readily seen in mixed lympho- al., 1998b, 1999), suggesting that Ly-49 receptors are
cyte or cell-mediated lympholysis assays (Wekerle et downmodulated by interactions with their ligand, rather
al., 1999b, 2000; Ito et al., 2001), none of these other than being calibrated to a specific level needed for toler-
approaches have been shown to lead to systemic tol- ance and “usefulness.” In vitro cytolytic assays showed
erance. a lack of tolerance of donor and host NK cells from
Calcineurin inhibitors such as cyclosporine and mixed chimeras to the host and donor, respectively,
FK506, which block priming for AICD by IL-2, have been
but preserved tolerance to self (Manilay et al., 1998b).
shown to block graft prolongation induced by costimula-
However, in vivo studies provide clear evidence of NK
tory blockade (Larsen et al., 1996; Kirk et al., 1999) and
cell tolerance to hematopoietic cells of the recipientrapamycin (Li et al., 1999) without BMT, apparently due
and donor strains (Y. Zhao et al., unpublished data).to the prevention of IL-2-induced priming for AICD (Li et
Likewise, in vivo studies have demonstrated NK cellal., 1999). In the model involving BMT with costimulatory
tolerance in irradiation chimeras (Kung and Miller, 1997;blockade (Wekerle et al., 1998), CYA only partially inhib-
Wu and Raulet, 1997) and in mice with mosaic expres-its deletion of donor-reactive T cells in the periphery
sion of an MHC transgene (Tg) (Johansson et al., 1997),(Wekerle et al., 2001). In models involving costimulatory
despite a lack of such tolerance following activation inblockade with or without HCT, passive (associated with
vitro (Johansson et al., 1997; Kung and Miller, 1997).cytokine withdrawal) cell death (Grillot et al., 1995) ap-
Thus, donor and host NK cells may be functionally toler-pears to play a critical role in deletion and tolerance
ant of alloantigens in mixed chimeras by different mech-induction (Wells et al., 1999; Wekerle et al., 2001).
anisms than those governing tolerance to self.Linked suppression and “infectious tolerance” have
been demonstrated in mice receiving minor histocom-
Potential of Mixed Chimerism to Induce Xenograftpatibility antigen–mismatched, MHC-identical skin grafts
Tolerance and Its Capacity to Tolerize Naturalunder cover of anti-CD40L and CD8 cell depletion (Graca
Antibody-Producing B Cellset al., 2000) and in mice accepting islet allografts after
Mixed chimerism can also induce tolerance across xe-treatment with CTLA4Ig (Tran et al., 1997). Such mecha-
nograft barriers (Ildstad and Sachs, 1984; Sharabi et al.,nisms may not be sufficiently powerful to maintain pri-
1990). If mAbs to NK1.1 and Thy1.2 are added to anti-mary skin graft tolerance in the MHC-mismatched set-
CD4 and CD8 mAbs, rat marrow engraftment and toler-ting. They do not appear to play a major role in
ance can be achieved in mice receiving non-myeloabla-maintaining the long-term tolerance induced by costim-
ulatory blockade with BMT (Wekerle et al., 1998), since tive conditioning with 3 Gy TBI and thymic irradiation,
Review
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through similar mechanisms to those described for allo- more difficult to induce in large animals than in rodents,
in large part due to differences in the types and amountsgeneic chimeras (Sharabi et al., 1990; Nikolic et al.,
of irradiation and reagents used in the different species.1998). Anti-Thy1.2 mAb is needed to deplete recipient
For example, T cell–depleting antibodies that accom-gd T cells, and anti-NK1.1 is needed to deplete recipient
plish the level of T cell depletion that has been achievedNK cells (Nikolic et al., 2001b), both of which play a
in mouse models for mixed chimerism induction havemuch more significant role in resisting the engraftment
not been evaluated in primate models. Stable mixedof xenogeneic than allogeneic marrow. Allogeneic mar-
chimerism has recently been achieved in MHC-identicalrow may be partially protected from NK cell–mediated
(but not MHC-mismatched) dogs using a non-mye-resistance due to the expression of class I molecules
loablative irradiation protocol involving a limited coursethat are recognized by NK cell surface inhibitory recep-
of pharmacological immunosuppression after BMTtors that cross-react on multiple class I alleles. Inhibitory
(Storb et al., 1997). Recent results in a porcine modelreceptors may not interact well across species barriers
(Fuchimoto et al., 2000; Huang et al., 2000) have applied(Seebach and Waneck, 1998), whereas at least some
approaches developed in mice to achieve mixed chime-NK cell activating receptors do function between spe-
rism across MHC barriers. Cynomolgus monkeys condi-cies (Idris et al., 1998; Nakamura et al., 1999).
tioned with anti-thymocyte globulin (ATG), fractionatedPigs are widely believed to be the most suitable xeno-
TBI (3 Gy), local TI (7 Gy), and splenectomy before trans-geneic donor species for transplantation to humans,
plantation of MHC-mismatched bone marrow and kid-but transplantation from this species is impeded by the
ney grafts, followed by 4 weeks of CyA treatment,presence in human sera of natural antibodies (Nab) that
achieve transient multilineage chimerism in associationcause hyperacute rejection of porcine vascularized xe-
with long-term kidney graft acceptance (Kawai et al.,nografts. In humans, the major specificity recognized
1995). While these studies provide important proof ofby Nab on porcine tissues is a ubiquitous carbohydrate
principle, in both large animal studies the level of Tepitope, Gala1-3Galb1-4GlcNAc-R (aGal). Humans lack
cell depletion achieved with available reagents was fara functional a1-3Gal transferase (GalT) enzyme, as do
inferior to that achieved in the murine model upon whichGalT knockout mice, which also make anti-aGal Nab.
they are based.Both preexisting and newly developing B cells produc-
Donor lymphocyte infusions (DLI) convert mixed chi-ing anti-aGal antibodies are tolerized by the induction
meras to full chimeras without causing GVHD (Sykes etof mixed chimerism in GalT knockout mice receiving
al., 1988). This observation provided an opportunity toaGal-expressing allogeneic or xenogeneic marrow (Yang
evaluate a protocol for mixed chimerism induction withet al., 1998; Ohdan et al., 1999). The induction of mixed
non-myeloablative conditioning in patients with hemato-xenogeneic chimerism prevents hyperacute rejection,
logic malignancies (Spitzer et al., 1999b), in an effort toacute vascular rejection, and cell-mediated rejection of
exploit lymphohematopoietic GVH reactions induced byprimarily vascularized cardiac xenografts (Ohdan et al.,
DLI in mixed chimeras to achieve graft-versus-tumor2001). Long-term chimeras produced in GalT knockout
effects without GVHD. The potential of this approachmice lack anti-Gal surface Ig-bearing cells in the spleen
to induce transplantation tolerance was evaluated in aand show tolerance in ELISPOT assays (Ohdan et al.,
patient who had a hematologic malignancy, multiple1999, 2001).
myeloma, and consequent renal failure. She received aIn mice achieving T and B cell tolerance to rat donors
simultaneous bone marrow and renal allograft from herdue to induction of mixed chimerism with non-myelo-
HLA-identical sister, and has now accepted her kidneyablative conditioning, chimerism gradually disappears
graft without any immunosuppression for over 2 years.over time, apparently due to a competitive advantage of
Similar to the primate model described above, in whichhost over donor hematopoietic cells (Gritsch and Sykes,
BMT has been shown to be essential for tolerance induc-1996). Achievement of xenogeneic hematopoietic re-
tion (Kawai et al., 1995), chimerism in this patient was
population is an even more formidable challenge in more
only transient (Spitzer et al., 1999a), suggesting that the
disparate species combinations. Innate immune barriers
kidney graft itself may participate in tolerance induction
to hematopoietic cell engraftment as well species speci- and/or maintenance after chimerism has played its initial
ficity of critical cytokines and adhesion molecules (Si- role. Because T cell depletion is only partial in these
mon et al., 1999) may limit the level of donor repopula- models, it is clear that the long-term central, deletional
tion. Donor species-specific cytokines can partially tolerance described above in murine models has not
overcome this barrier (Chen et al., 2000), but additional yet been achieved with non-myeloablative conditioning
barriers will need to be identified and surmounted before in monkeys or humans.
this approach can be successfully applied in the pig to Other clinical trials have involved the administration
primate species combination. of donor bone marrow from HLA-mismatched cadaveric
or living renal or liver allograft donors, without host myelo-
From Rodent Studies to the Clinic: suppressive or lymphoablative treatment, with the use
How Do We Get There? of conventional chronic immunosuppressive therapy
Tolerance induced by mixed chimerism in place of posttransplant. These studies were based on the obser-
chronic immunosuppressive therapy would be a drastic vation that many long-term organ allograft recipients
departure from current clinical practice in allograft recip- spontaneously exhibit lasting microchimerism (Starzl et
ients. Thus, efforts to translate from the above rodent al., 1992), which is only measurable by highly sensitive
models into clinical trials must be interceded by preclini- techniques. “Microchimerism” should be distinguished
cal, large animal studies to document the safety and from the mixed chimerism discussed above, in which
multilineage chimerism is readily measurable by flowefficacy of the approach. Chimerism has generally been
Immunity
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Idris, A.H., Iizuka, K., Smith, H.C., Scalzo, A.A., and Yokoyama, W.M.cytometry. Numerous attempts have been made to dem-
(1998). Genetic control of natural killing and in vivo tumor eliminationonstrate a relationship between microchimerism and toler-
by the Chok locus. J. Exp. Med. 188, 2243–2256.ance. While under certain circumstances microchimerism
Ildstad, S.T., and Sachs, D.H. (1984). Reconstitution with syngeneicmay contribute to a state of operational tolerance by
plus allogeneic or xenogeneic bone marrow leads to specific accep-
poorly defined mechanisms, tolerance is by no means tance of allografts or xenografts. Nature 307, 168–170.
assured in the presence of microchimerism (Schlitt et
Ito, H., Kurtz, J., Shaffer, J., and Sykes, M. (2001). CD4 T cell-
al., 1994). The administration of donor marrow with solid mediated alloresistance to fully MHC-mismatched allogeneic bone
organ allografts with standard chronic immunosuppres- marrow engraftment is dependent on CD40-CD40L interactions, and
sive therapy has augmented microchimerism, but no lasting T cell tolerance is induced by bone marrow transplantation
with initial blockade of this pathway. J. Immunol., in press.significant impact on acute rejection episodes or immu-
Johansson, M.H., Bieberich, C., Jay, G., Karre, K., and Hoglund, P.nosuppressive medication doses has yet been reported
(1997). Natural killer cell tolerance in mice with mosaic expression(Rugeles et al., 1997).
of major histocompatibility complex I transgene. J. Exp. Med. 186,The recent development of depleting, humanized
353–364.monoclonal antibodies against human T cells and
Kawai, T., Cosimi, A.B., Colvin, R.B., Powelson, J., Eason, J., Koz-against costimulatory molecules raises hope that the
lowski, T., Sykes, M., Monroy, R., Tanaka, M., and Sachs, D.H. (1995).
advances in rodent models described above in the de- Mixed allogeneic chimerism and renal allograft tolerance in cynomo-
velopment of minimal, nontoxic host conditioning regi- logous monkeys. Transplantation 59, 256–262.
mens for mixed chimerism induction will soon be applied Kenyon, N.S., Chatzipetrou, M., Masetti, M., Ranuncoli, A., Oliveira,
in large animal models and humans. Such efforts are M., Wagner, J.L., Kirk, A.D., Harlan, D.M., Burkly, L.C., and Ricordi,
C. (1999). Long-term survival and function of intrahepatic islet allo-likely to require more than one of these new reagents
grafts in rhesus monkeys treated with humanized anti-CD154. Proc.and thus will depend on the willingness of biotechnology
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